FIGURE 1




Relative Median Lifespan
(Relative to Mock)
2
1.8
1.6
1.4
1.2
1
0.8
0.6
0.4
0.2
0
DMSO
RDC5 (10 ug/ml)
RDC5 (1 ug/ml)
RDC5 (100 ng/ml)
RDC5 (10 ng/ml)
RDC5 (1 ng/ml)
RDC5 (100 pg/ml)
RDC5 (10 pg/ml)
RDC5 (1 pg/ml)
Treatment Regime

FIGURE 2



Bus8	Control Treatment	RDC5 1ug/ml	% increase wrt control	RDC5 10ug/ml	% increase wrt control
Healthspan	6.9	6.9	0.5	7.9	14
Median Lifespan	10.1	10.9	7.5	12.2	20

Bus8	Control Treatment	RDC5 20ug/ml	% increase wrt control	RDC5 40ug/ml	% increase wrt control
Healthspan	6.9	6.2	-9	6.7	-3
Median Lifespan	10.1	11.7	16	11.7	16

FIGURE 3




Quantified Oil-red-O Lipid Staining vs Age
Average corrected pixel intensity
60
50
40
30
20
10
0
0
2
4
6
8
Days post adulthood
DMSO
RDC5

FIGURE 4



- Background: Fischer,
- n=20 at outset but by 24m of age some natural death occurred and n=11 in control treated group and n=12 in RDC5 treated group.
- Dosing, subcutaneously once daily 6 days/week
- Dose: 1mg/kg/day sub. Cut.

FIGURE 5




Body Weight (g)
340
320
300
280
260
240
220
200
180
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24
Experiment Time-point (Week)
18 m of age
Treatment Starts
24 m of age
*
Healthy Adult Weight 220g - 250g
Control
RDC5 1 mg/kg/day S.C.

FIGURE 6



	Total Cholesterol	HDL	LDL	Ketone Bodies
Relative Change (%)	-40.52%	-26.27%	-30.98%	-12.57%
TTEST	0.02760826	0.001844555	0.029904164	0.535056823
Significant	Significant	Significant	Significant	Not Significant
	Reduction	Reduction	Reduction	Reduction

	Triglycerides	Glycerol	Free Fatty Acids
Relative Change (%)	-60.98%	-5.96%	-2.55%
TTEST	0.04176149	0.604489594	0.851673856
Significant	Significant	Not Significant	Not Significant
	Reduction	Reduction	Reduction

FIGURE 7



Ascomycin vs RDC5
Population Viability (%)
100
90
80
70
60
50
40
30
20
10
0
0
5
10
15
Days
Control Treatment
RDC5 (Sigma)
RDC5 (Evita)
Ascomycin

FIGURE 8



DihydroTacrolimus vs RDC5
Population Viability (%)
100
90
80
70
60
50
40
30
20
10
0
0
5
10
15
20
Days
Control
Dihydrotacrolimus (20ug/ml)
RDC5 (20ug/ml)

Figure 9



Dose Response for RDC5
Bus 8 Worm Healthspan & Median Lifespan
Efficacious Range
1 – 20ug/ml
Healthspan
Median Lifespan
% Change w.r.t Control
25
20
15
10
5
0
-5
-10
-15
0
10
20
30
40
50
RDC5 Dose (ug/ml)

Figure 10




Dose Response for RDC5
Bus 5 Worm Healthspan & Median Lifespan
Healthspan
Median Lifespan
% Change w.r.t Control
Efficacious Range
1 ~ 10ug/ml
RDC5 Dose (ug/ml)
40
35
30
25
20
15
10
5
0
-5
-10
0
10
20
30
40
50

FIGURE 11


Young_A single slice
7th Image of 32
3 months old
Untreated
VEH_20 single slice
7th Image of 32
24 months old
Control Treated
RDC5_33 single slic
7th Image of 32
24 months old
RDC5 Treated